Design: Randomised, open-label, two-period crossover bioequivalence study
Population: 52 healthy Chinese adults, fasting and fed cohorts
Primary outcome: Bioequivalence of generic versus reference teneligliptin
Effect: All exposure ratios within the 80-125% bounds; no serious adverse events

Teneligliptin, a DPP-4 inhibitor widely used for type 2 diabetes across Asia including India, is a candidate for lower-cost generic substitution if a generic behaves like the reference drug. This crossover study in 52 healthy adults compared a generic 40 mg tablet with the reference product, fasting and fed.

The generic was bioequivalent on every measure. For the area under the concentration curve and peak concentration, the 90% confidence intervals of the generic-to-reference ratios all fell within the standard 80 to 125% bounds, in both the fasting and fed states, with no serious adverse events.

The practical point is that this generic can substitute for the branded teneligliptin without expecting a different effect, which matters for affordability in settings where the drug is heavily used. Bioequivalence is an exposure comparison, not an outcomes trial, but it is the accepted basis for generic substitution of a drug like this.

Crossover bioequivalence study of generic versus reference teneligliptin 40 mg in 52 adults.
Exposure ratios fell within the standard 80 to 125% bounds, fasting and fed.
No serious adverse events occurred.
Teneligliptin is a DPP-4 inhibitor widely used for type 2 diabetes in Asia.
Bioequivalence supports generic substitution for cost without expecting a different effect.

Why it matters

It gives a concrete basis for lower-cost prescribing of a heavily used DPP-4 inhibitor.

The statistics, in plain English

Bioequivalence means the generic produced blood levels within 80 to 125% of the reference, the regulatory window judged clinically indistinguishable. It compares drug exposure, not clinical outcomes, which is the standard for generics of well-characterised oral drugs.